MediWound Stock Forecast, Price & News

-0.09 (-2.39 %)
(As of 08/4/2021 01:36 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5,534 shs
Average Volume497,773 shs
Market Capitalization$99.97 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MediWound logo

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.63 out of 5 stars

Medical Sector

930th out of 1,309 stocks

Medicinals & Botanicals Industry

5th out of 18 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

MediWound (NASDAQ:MDWD) Frequently Asked Questions

Is MediWound a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound
or view top-rated stocks.

What stocks does MarketBeat like better than MediWound?

Wall Street analysts have given MediWound a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MediWound wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting MediWound?

MediWound saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 313,700 shares, an increase of 172.3% from the June 15th total of 115,200 shares. Based on an average daily trading volume, of 312,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.3% of the company's stock are sold short.
View MediWound's Short Interest

When is MediWound's next earnings date?

MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for MediWound

How can I listen to MediWound's earnings call?

MediWound will be holding an earnings conference call on Tuesday, August 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) issued its earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.02. The biopharmaceutical company earned $5.85 million during the quarter, compared to analyst estimates of $5.30 million. MediWound had a negative trailing twelve-month return on equity of 125.38% and a negative net margin of 41.37%.
View MediWound's earnings history

How has MediWound's stock price been impacted by Coronavirus (COVID-19)?

MediWound's stock was trading at $2.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MDWD shares have increased by 58.9% and is now trading at $3.67.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MDWD?

4 brokerages have issued 1 year target prices for MediWound's stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate MediWound's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 104.4% from the stock's current price.
View analysts' price targets for MediWound
or view top-rated stocks among Wall Street analysts.

Who are MediWound's key executives?

MediWound's management team includes the following people:
  • Mr. Sharon Malka CPA, MBA, Chief Exec. Officer (Age 49, Pay $520k)
  • Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 75, Pay $440k)
  • Mr. Boaz Gur-Lavie CPA, M.B.A., Chief Financial Officer (Age 47, Pay $341k)
  • Mr. Yaron Meyer, Exec. VP, Gen. Counsel & Corp. Sec. (Age 42, Pay $315k)
  • Dr. Ety Klinger, Chief R&D Officer (Age 59, Pay $375k)
  • Mr. Stephen T. Wills CPA, CPA, MST, Exec. Chairman (Age 64)

Who are some of MediWound's key competitors?

What other stocks do shareholders of MediWound own?

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Who are MediWound's major shareholders?

MediWound's stock is owned by a number of retail and institutional investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (4.39%).

Which institutional investors are selling MediWound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd..

How do I buy shares of MediWound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $3.67.

How much money does MediWound make?

MediWound has a market capitalization of $99.97 million and generates $21.76 million in revenue each year. The biopharmaceutical company earns $-9,200,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does MediWound have?

MediWound employs 75 workers across the globe.

What is MediWound's official website?

The official website for MediWound is

Where are MediWound's headquarters?

MediWound is headquartered at 42 HAYARKON STREET, YAVNE L3, 8122745.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.